Latest Markets Business Premium Personal Finance IPOs

Zydus Cadila Signs Pact With Gilead To Make Remdesivir

Reuters

Drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.

Drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.

lock-gif
Register for Free
to continue reading
Sign Up with Google
OR
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES

RECOMMENDED FOR YOU

CFO Leaders: The Making Of Five Star CFOs 
timelogo Jan 14, 2021
Stocks Rise, Treasuries Fall on Stimulus Bets: Markets Wrap
timelogo Aug 19, 2019
Stocks End Record-Setting Week With Further Gains: Markets Wrap
timelogo Jul 15, 2019
The Mutual Fund Show: The Dos And Don’ts Of Online Investing
timelogo Apr 27, 2019

POPULAR

1
Upcoming Stock Splits — Indo Thai Securities, Algoquant Fintech, Bemco Hydraulics
2
Bonus Issues This Week — Meghna Infracon Infrastructure, Alkosign, Dynamic Cables, Roto Pumps
3
Pregnancy, Prices, And Posh Perks: New Age Whimsies To Some Bare Necessities
4
Aditya Birla Group at Crossroads: Cement Arm Faces CCI Heat, Paints Division Takes on Asian Paints
5
Musk Declares ‘America Party’ Formed After Trump’s Bill Passes